Aldeyra Therapeutics, Inc. Common Stock ALDX
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-17T01:22:17.735Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-17T00:55:22.048118142Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-17T01:22:17.209923+00:00
Aldeyra Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 1.42 | 583.1% | 111.1% | 0.55 | 402.3% | 29.7% |
| 25Δ | 1.35 | 601.4% | 103.8% | 0.61 | 419.6% | 27.5% |
| 30Δ | 1.27 | 619.7% | 96.6% | 0.66 | 436.9% | 25.3% |
| 35Δ | 1.19 | 637.9% | 89.4% | 0.71 | 454.2% | 23.1% |
| 40Δ | 1.11 | 656.2% | 82.1% | 0.76 | 471.5% | 21.0% |
| 45Δ | 1.03 | 674.5% | 74.9% | 0.81 | 488.8% | 18.8% |
| 50Δ | 0.96 | 692.8% | 67.7% | 0.86 | 506.2% | 16.6% |
| 55Δ | 0.88 | 711.0% | 60.4% | 0.91 | 523.5% | 14.4% |
| 60Δ | 0.80 | 729.3% | 53.2% | 0.96 | 540.8% | 12.2% |
| 65Δ | 0.72 | 747.6% | 45.9% | 1.03 | 553.9% | 10.1% |
| 70Δ | 0.65 | 765.8% | 38.7% | 1.15 | 555.2% | 8.5% |
| 75Δ | 0.57 | 784.1% | 31.5% | 1.26 | 556.5% | 6.8% |
| 80Δ | 1.38 | 557.8% | 5.2% | |||
20Δ
- Pseudo strike
- 1.42
- IV
- 583.1%
- B/E move
- 111.1%
- Pseudo strike
- 0.55
- IV
- 402.3%
- B/E move
- 29.7%
25Δ
- Pseudo strike
- 1.35
- IV
- 601.4%
- B/E move
- 103.8%
- Pseudo strike
- 0.61
- IV
- 419.6%
- B/E move
- 27.5%
30Δ
- Pseudo strike
- 1.27
- IV
- 619.7%
- B/E move
- 96.6%
- Pseudo strike
- 0.66
- IV
- 436.9%
- B/E move
- 25.3%
35Δ
- Pseudo strike
- 1.19
- IV
- 637.9%
- B/E move
- 89.4%
- Pseudo strike
- 0.71
- IV
- 454.2%
- B/E move
- 23.1%
40Δ
- Pseudo strike
- 1.11
- IV
- 656.2%
- B/E move
- 82.1%
- Pseudo strike
- 0.76
- IV
- 471.5%
- B/E move
- 21.0%
45Δ
- Pseudo strike
- 1.03
- IV
- 674.5%
- B/E move
- 74.9%
- Pseudo strike
- 0.81
- IV
- 488.8%
- B/E move
- 18.8%
50Δ
- Pseudo strike
- 0.96
- IV
- 692.8%
- B/E move
- 67.7%
- Pseudo strike
- 0.86
- IV
- 506.2%
- B/E move
- 16.6%
55Δ
- Pseudo strike
- 0.88
- IV
- 711.0%
- B/E move
- 60.4%
- Pseudo strike
- 0.91
- IV
- 523.5%
- B/E move
- 14.4%
60Δ
- Pseudo strike
- 0.80
- IV
- 729.3%
- B/E move
- 53.2%
- Pseudo strike
- 0.96
- IV
- 540.8%
- B/E move
- 12.2%
65Δ
- Pseudo strike
- 0.72
- IV
- 747.6%
- B/E move
- 45.9%
- Pseudo strike
- 1.03
- IV
- 553.9%
- B/E move
- 10.1%
70Δ
- Pseudo strike
- 0.65
- IV
- 765.8%
- B/E move
- 38.7%
- Pseudo strike
- 1.15
- IV
- 555.2%
- B/E move
- 8.5%
75Δ
- Pseudo strike
- 0.57
- IV
- 784.1%
- B/E move
- 31.5%
- Pseudo strike
- 1.26
- IV
- 556.5%
- B/E move
- 6.8%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.38
- IV
- 557.8%
- B/E move
- 5.2%
Options history
History unavailable
Biotechnology
ALEC
Alector, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of neurodegenerative diseases. The company is headquartered in South San Francisco,…
More →ALLO
Allogene Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and markets genetically engineered allogeneic T-cell therapies for the treatment of cancer. The…
More →ALMS
Description unavailable
More →ALNY
Description unavailable
More →ALT
Altimmune, Inc., a clinical-stage biopharmaceutical company, focuses on the development of intranasal vaccines, immunomodulatory therapies, and treatments for liver disease. The…
More →ALXO
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. The company is headquartered in Burlingame,…
More →